axsome Therapeutics Reports P-III (ACCORD) Trial Results of AXS-05 for the Treatment of Alzheimer’s Disease Agitation
Shots:
- The P-III (ACCORD) trial evaluates AXS-05 vs PBO in a ratio (1:1) in 178 patients with AD agitation. 108 were randomized to continue on AXS-05 or switch to PBO
- The trial met the 1EPs & 2EPs i.e., significantly delayed time to relapse & prevented relapse (7.5% vs 25.9%), an improvement over baseline in agitation symptoms, improvement in agitation (66.3% @2wk.) and 86.3% @5wk. as assessed using mADCS-CGIC; 68% & 89% by PGI-C scale
- Mean reduction from baseline in CMAI total score @1/2/5wk. was 6.7/11.0/20.6 points & clinical response (21.8%/40.4%/70.0%), improvement in caregiver distress, caregiver burden, QoL & depressive symptoms after being treated with open-label AXS-05 @4 & 8wk., rate of AEs (28.3% vs 22.2%), AEs leads to treatment discontinuations (0% vs 1.9%)
Ref: axsome | Image: axsome
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
